A Phase I, single-dose, parallel-group, open-label study evaluating the effect of renal impairment and hemodialysis on avibactam pharmacokinetics and safety in subjects with renal impairment and healthy controls.

Trial Profile

A Phase I, single-dose, parallel-group, open-label study evaluating the effect of renal impairment and hemodialysis on avibactam pharmacokinetics and safety in subjects with renal impairment and healthy controls.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Avibactam (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Aug 2016 New trial record
    • 12 Jul 2016 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top